BioVersys AG

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.

We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.

Website

News

News

BioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million

  • Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis
  • GSK to participate in Series C Extension with equity investment
  • Series C financing round extended overall by CHF 12.3 million to CHF 44.9 million
News

BioVersys announces first patient dosed in Phase 2a clinical trial

BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis…

Building C3
Industry Biotech
Research Topics Antimicrobial Resistance (AMR)
Employees 17
Founding year 2010
This website uses cookies. Read our data privacy statement to find out how we use cookies and how you can change your settings.